US Genomics Market Analysis, Size, and Forecast 2026-2030

US Genomics Market Size 2026-2030

The us genomics market size is valued to increase by USD 9.25 billion, at a CAGR of 12.9% from 2025 to 2030. Technological innovations in next generation sequencing and bioinformatics integration will drive the us genomics market.

Major Market Trends & Insights

• By Application - Diagnostic segment was valued at in 2024
• By End-user - Hospitals and clinics segment accounted for the largest market revenue share in 2024

Market Size & Forecast

• Market Opportunities: USD 13.51 billion
• Market Future Opportunities: USD 9.25 billion
• CAGR from 2025 to 2030 : 12.9%

Market Summary

• The genomics market in the US is undergoing a significant transformation, moving beyond foundational research to become a cornerstone of clinical practice. This evolution is driven by advancements in high-throughput sequencing and sophisticated bioinformatics that enable the rapid analysis of complex genetic data. As a result, applications in precision medicine, particularly for oncology and rare diseases, are expanding.
• The market is also characterized by a strong emphasis on integrating genomic information into routine healthcare to improve diagnostic accuracy and tailor therapeutic strategies. A key business scenario involves a hospital system implementing comprehensive genomic profiling for all new oncology patients.
• This initiative allows oncologists to select targeted therapies based on the specific molecular alterations of a tumor, which can lead to better patient outcomes and reduce expenditures on ineffective treatments.
• However, the increasing volume of sensitive patient data necessitates robust data security measures and clear regulatory frameworks to maintain public trust and ensure compliance, which remain critical areas of focus for industry participants.

What will be the Size of the US Genomics Market during the forecast period?

Get Key Insights on Market Forecast (PDF) Request Free Sample

How is the US Genomics Market Segmented?

The us genomics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2026-2030, as well as historical data from 2020-2024 for the following segments.

By Application Insights

The diagnostics segment is estimated to witness significant growth during the forecast period.

Request Free Sample

The Diagnostics segment was valued at in 2024 and showed a gradual increase during the forecast period.

Request Free Sample

Market Dynamics

Our researchers analyzed the data with 2025 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

• The trajectory of the genomics market in the US is increasingly influenced by the interplay between technological progress and economic realities. While the decreasing cost of whole genome sequencing makes large-scale studies more feasible, it simultaneously amplifies challenges in genomic data security, creating a pressing need for advanced encryption and robust compliance frameworks.
• The rise of AI in genomic data analysis is pivotal for interpreting the vast datasets generated, with some algorithms now processing complex variant information 40% faster than manual methods. This computational power is essential for realizing the full benefits of long-read sequencing technologies, which offer a more comprehensive view of genetic structures.
• However, translating these technological gains into clinical practice hinges on a clear pathway for regulatory clearance. The FDA approval for companion diagnostics remains a critical bottleneck and a key determinant for the commercial viability of new targeted therapies, directly impacting how innovations are integrated into standard patient care.
• Businesses must navigate this landscape by balancing investment in cutting-edge technology with rigorous attention to regulatory and data privacy requirements.

What are the key market drivers leading to the rise in the adoption of US Genomics Industry?

• Technological innovations in next-generation sequencing and the integration of bioinformatics are key drivers for the market.

• Key drivers for the genomics market in the US include technological maturation and increased accessibility.
• The expansion of cloud-based genomic data platforms enables seamless collaboration, while a move toward decentralized genomic testing is bringing powerful analytics closer to the point of care.
• The development of companion diagnostics is creating a direct link between testing and treatment, fostering the growth of personalized healthcare solutions.
• This is particularly evident in oncology, where comprehensive genomic profiling and analysis of molecular alterations are becoming standard for tumor molecular profiling and biomarker discovery.
• Such integrated approaches, part of a broader clinical genomics integration, have been shown to improve therapy selection efficacy by up to 20% in specific cancer types.
• The refinement of genomic data management systems further supports the application of these tools in routine care.

What are the market trends shaping the US Genomics Industry?

• The acceleration of precision medicine and the clinical integration of targeted oncology represent a significant forthcoming market trend.

• A primary trend shaping the genomics market is the deep integration of precision medicine into clinical workflows, particularly for targeted oncology therapies. The use of whole genome sequencing and spatial transcriptomics is becoming more common, moving beyond research to active diagnostics. This shift is driven by advancements in next-generation sequencing, which have drastically lowered costs and improved data output.
• Innovations in long read sequencing are resolving complex genomic regions previously inaccessible with short read sequencing methods, improving diagnostic accuracy for rare disease diagnostics by over 10%. Furthermore, sophisticated genomic data analysis and bioinformatics integration are enabling the identification of novel drug targets, accelerating drug discovery genomics.
• As a result, non-invasive prenatal testing adoption has increased, with some providers reporting a 15% rise in test volumes year-over-year.

What challenges does the US Genomics Industry face during its growth?

• Concerns regarding data security and the complexities of regulatory compliance present a key challenge affecting industry growth.

• A significant challenge confronting the genomics market involves navigating data security and regulatory complexities. As high-throughput sequencing generates massive volumes of sensitive information, including cell-free DNA data, ensuring patient privacy is paramount. The risk is compounded by the increasing use of advanced computing in genomics and real-time surgical data analysis, which expands the potential for breaches.
• Furthermore, establishing clear standards for regulated research environments remains a complex task. For instance, the implementation of new data protection protocols can increase compliance overhead by up to 25% for laboratories handling multiomic diagnostic testing.
• The need for robust frameworks for non-invasive genomic analysis and cancer risk assessment is critical to maintaining public trust and fostering participation in genomic medicine, including the adoption of next-generation surgery solutions.

Exclusive Technavio Analysis on Customer Landscape

The us genomics market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the us genomics market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

Customer Landscape of US Genomics Industry

Competitive Landscape

Companies are implementing various strategies, such as strategic alliances, us genomics market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.

Agilent Technologies Inc. - Offerings encompass a range of advanced genomic solutions, from sequencing platforms and reagents to integrated bioinformatics, designed to accelerate research and enable precision medicine applications.

The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• Agilent Technologies Inc.
• Bio Rad Laboratories Inc.
• Caris Life Sciences
• CENTOGENE NV
• Danaher Corp.
• Eurofins Scientific SE
• F. Hoffmann La Roche Ltd.
• Illumina Inc.
• LetsGetChecked
• Myriad Genetics Inc.
• Natera Inc.
• Oxford Nanopore Technologies
• Pacific Biosciences Inc.
• Personalis Inc.
• QIAGEN N.V.
• Revvity Inc.
• Thermo Fisher Scientific Inc.
• Twist Bioscience Corp.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Recent Development and News in Us genomics market

• In September 2024, 23andMe reached a settlement for $30 million to resolve a class-action lawsuit following a significant data breach, highlighting the increasing legal and financial risks associated with data governance in the genomics sector.
• In October 2024, Illumina launched its MiSeq i100 Series, a new line of benchtop sequencers designed to make next-generation sequencing more accessible for laboratories through simplified logistics and faster operation.
• In December 2024, the US National Science Foundation highlighted significant investments made during the year to bolster scientific leadership, focusing on areas including AI, biotechnology, and advanced computing to support long-term innovation.
• In January 2025, IQVIA initiated a strategic collaboration with NVIDIA to advance the application of agentic AI in healthcare, aiming to automate complex workflows and enhance the development of precise, scalable AI solutions.

Dive into Technavio’s robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled US Genomics Market insights. See full methodology.

Request Free Sample

Research Analyst Overview

• The genomics market in the US is characterized by continuous innovation, where foundational technologies like next-generation sequencing and bioinformatics integration are enabling increasingly complex applications. The market is advancing from short read sequencing to long read sequencing and single molecule real-time sequencing, offering greater resolution for whole genome sequencing.
• This technological shift supports the expansion of clinical genomics tests, including advanced genetic testing and hereditary cancer testing for applications in precision medicine. Technologies such as single cell sequencing and spatial transcriptomics provide unprecedented insights, while the development of companion diagnostics and liquid biopsy technology is transforming oncology.
• Key operational components include automated sample preparation, DNA synthesis platforms, and target enrichment panels for PCR systems and microarray platforms. The management of cloud-based genomic data is crucial, especially as decentralized genomic testing becomes more prevalent. Advances in DNA quantification, gene expression analysis, and multiomic diagnostic testing are further refining molecular biology workflows and genetic testing solutions.
• This ecosystem, supported by nucleic acid analysis and open-source genomic databases, has enabled a 30% reduction in data processing times at leading research centers, accelerating the pace of discovery.

What are the Key Data Covered in this US Genomics Market Research and Growth Report?

• What is the expected growth of the US Genomics Market between 2026 and 2030?

  • USD 9.25 billion, at a CAGR of 12.9%

• What segmentation does the market report cover?

  • The report is segmented by Application (Diagnostic, Drug discovery, and Others), End-user (Hospitals and clinics, Academic and research institutes, Pharmaceutical and biotechnology companies, and Others), Solution (Products, and Services) and Geography (North America)

• Which regions are analyzed in the report?

  • North America

• What are the key growth drivers and market challenges?

  • Technological innovations in next generation sequencing and bioinformatics integration, Data security and regulatory compliance issues

• Who are the major players in the US Genomics Market?

  • Agilent Technologies Inc., Bio Rad Laboratories Inc., Caris Life Sciences, CENTOGENE NV, Danaher Corp., Eurofins Scientific SE, F. Hoffmann La Roche Ltd., Illumina Inc., LetsGetChecked, Myriad Genetics Inc., Natera Inc., Oxford Nanopore Technologies, Pacific Biosciences Inc., Personalis Inc., QIAGEN N.V., Revvity Inc., Thermo Fisher Scientific Inc. and Twist Bioscience Corp.

Market Research Insights

• The integration of advanced analytics is reshaping the genomics market in the US, with applications in precision medicine integration and targeted oncology therapies showing significant momentum. The use of sophisticated genomic data analysis improves biomarker discovery rates by up to 25% compared to traditional methods.
• Furthermore, the adoption of specialized tumor molecular profiling allows for more effective personalized healthcare solutions, reducing trial-and-error in treatment selection. The expansion of non-invasive prenatal testing and rare disease diagnostics is broadening the clinical utility of genomics. As a result, some laboratories leveraging automated clinical genomics integration have reported a 30% decrease in sample processing times, enhancing operational efficiency.
• These dynamics underscore a market shift toward data-driven, outcome-focused healthcare.

We can help! Our analysts can customize this us genomics market research report to meet your requirements.

Get in touch